

University of Dundee

DOCTOR OF PHILOSOPHY

Cardiovascular events and mortality in systemic sclerosis: A study of the effect of Iloprost on these and on disease progression The SSTEP Study (Systemic Sclerosis Trial of Events and Progression)

McSwiggan, Stephen John

Award date:
2014

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

DOCTOR OF PHILOSOPHY

Cardiovascular events and mortality in systemic sclerosis: A study of the effect of Iloprost on these and on disease progression

The SSTEP Study (Systemic Sclerosis Trial of Events and Progression)

Stephen John McSwiggan

2014

University of Dundee

Conditions for Use and Duplication

Copyright of this work belongs to the author unless otherwise identified in the body of the thesis. It is permitted to use and duplicate this work only for personal and non-commercial research, study or criticism/review. You must obtain prior written consent from the author for any other use. Any quotation from this thesis must be acknowledged using the normal academic conventions. It is not permitted to supply the whole or part of this thesis to any other person or to post the same on any website or other online location without the prior written consent of the author. Contact the Discovery team (discovery@dundee.ac.uk) with any queries about the use or acknowledgement of this work.

Cardiovascular events and mortality in
systemic sclerosis: A study of the effect of
Iloprost on these and on disease progression

The SSTEP Study
(Systemic Sclerosis Trial of Events and
Progression)

Stephen John McSwiggan

Thesis submitted for the degree of
Doctor of Philosophy
University of Dundee
July 2014

TABLE OF CONTENTS

Table of contents	ii
List of figures and tables	xi
<i>Figures</i>	<i>xi</i>
<i>Tables</i>	<i>xii</i>
Abbreviations	xiv
Acknowledgements	xix
Signed declaration	xx
Supervisor statement	xxi
Summary	xxii
Abstracts and presentations	xxiv
<i>Abstracts</i>	
<i>Oral presentations</i>	
<i>Poster presentations</i>	

CHAPTER 1: SYSTEMIC SCLEROSIS

1.1 Introduction	1
1.2 Epidemiology	3
<i>1.2.1 Age and disease subset</i>	<i>3</i>
<i>1.2.2 Gender differences</i>	<i>4</i>
<i>1.2.3 Race</i>	<i>5</i>
<i>1.2.4 Cluster/geographical Variations</i>	<i>6</i>
1.3 Aetiology	7
<i>1.3.1 Angiogenesis in SSc</i>	<i>9</i>

1.3.2 Possible triggers for SSc	10
1.3.3 Pollutants and environmental triggers	11
1.4 Classification	12
1.5 Clinical presentation	16
1.5.1 Raynaud's disease	16
1.5.2 Scleroderma	17
1.5.3 Calcinosis	18
1.5.4 Telangiectasia	19
1.5.5 Gastrointestinal tract symptoms	20
1.5.6 Dyspnoea	20
1.5.7 Conduction defects and arrhythmias	20
1.6 Diagnosis	21
1.6.1 Clinical history and physical examination	21
1.6.2 Nail fold capillaroscopy	22
1.6.3 Antibody testing	22
1.6.4 Overlap syndrome	23
1.6.5 Mixed connective tissue diseases	23
1.7 Systematic organ screening	24
1.7.1 Skin assessment	24
1.7.2 Renal assessment	25
1.7.3 Pulmonary assessment	26
1.7.4 Cardiac assessment	27
1.7.4.1 Pulmonary hypertension	27
1.7.4.2 Assessing conduction defects and arrhythmias	29
1.7.5 Gastrointestinal tract assessment	29

1.8 Microvascular disease in SSc	30
1.9 Macrovascular disease in SSc	30
1.10 Pharmacological management of SSc	33
<i>1.10.1 Symptomatic treatments</i>	36
<i>1.10.1.1 Raynaud's</i>	36
<i>1.10.1.2 Skin therapies</i>	36
<i>1.10.1.3 Renal Crises</i>	37
<i>1.10.1.4 GI symptoms</i>	37
<i>1.10.2 Disease-modifying treatments</i>	37
<i>1.10.2.1 Methotrexate</i>	37
<i>1.10.2.2 Minocycline</i>	38
<i>1.10.2.3 D-Penicillamine</i>	38
<i>1.10.2.4 Cyclophosphamide</i>	39
<i>1.10.2.5 Mycophenolate mofetil or mycophalate sodium</i>	39
1.11 Chapter summary	40
CHAPTER 2: ILOPROST	41
2.1 Introduction	41
2.2 Prostanoids	41
2.3 Iloprost chemistry	41
2.3 Iloprost mode of action	42
<i>2.3.1 Effect on platelet function</i>	43
<i>2.3.2 Effect on white cell function</i>	44
<i>2.3.3 Effect on the coagulation system</i>	45
<i>2.3.4 Effect on lactate and pyruvate levels</i>	45

2.3.5	<i>Effect on the microcirculation</i>	46
2.3.6	<i>Effects on the macrocirculation</i>	46
2.3.7	<i>Endothelial repair</i>	46
2.4	Uses of intravenous Iloprost	47
2.5	Safety and side effects of oral Iloprost	48
2.6	Chapter summary and rationale for doctoral study	50
CHAPTER 3:	METHODS	52
3.1	Introduction	52
3.2	Study design	52
3.2.1	<i>Trial oversight committees and good clinical practice</i>	53
3.2.1.1	<i>Trial Steering Committee</i>	56
3.2.1.2	<i>Data Safety and Monitoring Board</i>	56
3.2.1.3	<i>Trial Management Group</i>	57
3.2.1.4	<i>Role of Author (Mr McSwiggan)</i>	57
3.2.2	<i>Ethics and Regulatory Review</i>	58
3.2.3	<i>Study drug supply</i>	59
3.2.4	<i>Iloprost and placebo composition</i>	59
3.2.5	<i>Data analyses</i>	60
3.2.5.1	<i>Power calculation & sample size</i>	60
3.2.5.2	<i>Proposed statistical plan</i>	60
3.2.5.3	<i>Planned recruitment rate</i>	60
3.2.5.4	<i>Compliance</i>	61
3.2.5.5	<i>Likely rate of loss to follow-up</i>	61
3.2.5.6	<i>Proposed frequency of analyses</i>	61

3.2.6 Outcome measures	62
3.2.6.1 Primary outcome measures	62
3.2.6.2 Secondary outcome measures	63
3.2.6.3 Definitions of SSTEP study endpoints	63
3.2.6.4 Clinical Endpoints Committee process	65
3.2.7 Inclusion and exclusion criteria	65
3.2.7.1 Inclusion criteria	66
3.2.7.2 Exclusion criteria	68
3.2.8 Study visit schedule	69
3.2.8.1 Screening visit	70
3.2.8.2 Randomisation visit	71
3.2.8.3 Regular monitoring visits and annual review visits	72
3.3. Data collection	72
3.3.1 Data collection metrics	72
3.3.1.1 Demographic data	73
3.3.1.2 Smoking history	73
3.3.1.3 Alcohol intake	73
3.3.1.4 Clinical history	73
3.3.1.5 Medical and surgical history	73
3.3.1.6 Cardiovascular history	74
3.3.1.7 Physical examination	74
3.3.1.8 Clinical assessment	74
3.3.1.9 Ankle brachial index	74
3.3.1.10 Electrocardiogram	76
3.3.1.11 Blood tests	76

3.3.1.12 <i>Immunology blood testing</i>	77
3.3.1.13 <i>Routine urinalysis</i>	78
3.3.2 <i>Organ Screening</i>	78
3.3.2.1 <i>Pulmonary function testing</i>	78
3.3.2.2 <i>Echocardiography</i>	80
3.3.2.3 <i>Renal 24 hour urine creatinine clearance</i>	81
3.3.2.4 <i>Nuclear glomerular filtration rate</i>	82
3.3.3 <i>Concomitant medication checks and coding</i>	82
3.4 Adverse event monitoring	83
3.4.1 <i>Definitions of adverse events</i>	83
3.4.2 <i>Detecting adverse events and serious adverse events</i>	84
3.4.3 <i>Recording adverse events and serious adverse events</i>	85
3.4.4 <i>Evaluation of adverse events and serious adverse events</i>	85
3.4.5 <i>Reporting of SAEs/ SARs/ SUSARs</i>	88
3.5 Study sites and trial management	88
3.6 Chapter summary	90
CHAPTER 4: RESULTS	91
4.1 Introduction	91
4.2 Recruitment by centres	91
4.3 Recruitment of participants	94
4.4 Demographics and clinical characteristics	94
4.5 Endpoint analyses	101

4.5.1 Primary outcome measures	101
4.5.1.1 Analysis of deaths alone	102
4.5.1.2 Analysis of cardiovascular endpoints	105
4.5.2 Organ screening endpoints analysis	106
4.6 Withdrawal from randomised treatment	112
4.7 On treatment analysis	114
4.8 Concomitant medication	114
4.8.1 Intravenous Iloprost	117
4.9 Safety analysis	119
4.9.1 Elective admissions	120
4.9.2 Serious unexpected severe adverse reactions	120
4.9.3 Complications of SSc serious adverse events	120
4.9.4 Analysis of serious adverse reports per group	122
4.9.4.1 Infections	122
4.9.4.2 Gastrointestinal tract	123
4.9.4.3 Cancers	123
4.9.4.4 Cardiovascular	124
4.9.4.5 Respiratory	124
4.9.4.6 Psychiatric	124
4.9.4.7 Neurological	125
4.9.4.8 Haematological	125
4.9.4.9 Musculoskeletal/Dermatological	125
4.9.4.10 Urgent Surgery	125
4.9.4.11 Renal	126

4.9.4.12 <i>Endocrine</i>	126
4.9.5 <i>Safety reporting</i>	130
4.10 Conclusion	130
CHAPTER 5: DISCUSSION	131
5.1 Introduction	131
5.2 General discussion	131
5.2.1 <i>Oral Iloprost therapy and reduction in coronary and CV events</i>	132
5.2.2 <i>Oral Iloprost therapy and SSc disease progression</i>	133
5.2.3 <i>Challenges of trial management</i>	133
5.2.4 <i>Patient population</i>	134
5.2.5 <i>Safety</i>	137
5.3 Strengths and limitations of the study	138
5.4 Concluding remarks	140
5.5 Further studies	141
REFERENCES	142
APPENDICES	
Appendix 1 Committees flow chart	159
Appendix 2 Ethics Committee approvals	160
Appendix 3 MHRA approvals	168
Appendix 4 Clinical Endpoints Committee guidelines	176

Appendix 5	Patient information leaflets	189
Appendix 6	Consent forms	196
Appendix 7	GP letter	200
Appendix 8	Abbreviated version of CRF	201
Appendix 9	Process for CRF delivery to data management	230

LIST OF FIGURES AND TABLES

Figures

Figure 1.1 Cellular interactions in pathogenesis of systemic sclerosis (SSc)	11
Figure 1.2 Raynaud's phenomenon	16
Figure 1.3 Scleroderma on hand and infected nail bed	18
Figure 1.4 Sclerodactyly (early puffy fingers)	18
Figure 1.5 X-ray showing subcutaneous calcification of hand	19
Figure 1.6 Infected calcification on thumb	19
Figure 1.7 Telangiectasia on fingers	19
Figure 1.8 Nail fold capillaroscopy on fingers of SSc patient	22
Figure 1.9 Algorithm for treatment of severe progressive SSc	35
Figure 2.1 Chemical structure of Iloprost: molecular formula $C_{22}H_{32}O_4$	42
Figure 2.2 Scanning electron microscope image of platelet aggregation	45
Figure 3.1 Trial timeline for SSTEP Study	55
Figure 3.2 Proximal scleroderma on hand and forearm	67
Figure 3.3 Measurements of ABIs	75
Figure 3.4 Measurement of PFTs and gas transfer	79
Figure 3.5 Doppler echocardiography image of tricuspid regurgitation	81
Figure 3.6 Study site locations across UK and Ireland	90
Figure 4.1 Consort diagram of patient flow through study	93
Figure 4.2 Comparison of survival free from death or CV event	102
Figure 4.3 Comparison of rate of deaths in the Iloprost v placebo groups	104
Figure 4.4 Breakdown of reported causes of death in placebo group	104

Figure 4.5 Breakdown of reported causes of death in iloprost group	105
Figure 4.6 Comparison of time to a CV endpoint for Iloprost v placebo	106
Figure 4.7 Comparison of ‘medication survival’ Iloprost v placebo	112

TABLES

Table 1.1 Demographic comparisons of SSc patients	4
Table 1.2 Prevalence of SSc reported from epidemiology studies	5
Table 1.3 Clusters of higher prevalence of SSc	6
Table 1.4 Preliminary criteria for the classification of SSc	14
Table 1.5 Criteria for classification of diffuse and limited cutaneous SSc	15
Table 1.6 Criteria for classification of limited SSc	15
Table 3.1 Study visit schedule	69
Table 3.2 Safety blood measurements	77
Table 3.3 Definitions of causality for AEs	86
Table 3.4 Definitions of severity for AEs	87
Table 3.5 Definitions of expectedness for ARs	88
Table 4.1 Recruitment numbers per site for the SSTEP study	92
Table 4.2 Demographics of SSTEP study participants	95
Table 4.3 Disease characteristics on entry to the study	97
Table 4.4 Clinical findings at screening	99
Table 4.5 Potential endpoints submitted to and total confirmed by CEC and/or trial statistician	108
Table 4.6 Summary of frequency of clinical endpoints for organ screening tests, compared per group (Iloprost v placebo)	111
Table 4.7 Comparison of reasons noted for withdrawal from treatment	113

Table 4.8 Concomitant medication compared between iloprost and placebo groups	116
Table 4.9 Number of treatments with IV Iloprost	118
Table 4.10 Breakdown of SAE's reported to DSMB (9th April 2002- 31st Jan 2009)	119
Table 4.11 Complications of SSc, breakdown of SAE reports	122
Table 4.12 Breakdown of 'Other' reported SAEs	126

ABBREVIATIONS

ABI	Ankle brachial index
ACR	American College of Rheumatology
ACEi	Angiotensin-converting-enzyme inhibitor
ACA	Anti-centromere antibody
AE	Adverse event
ALT	Alanine aminotransferase
ANA	Anti-nuclear antibody
AR	Adverse reaction
ARA	American Rheumatology Association
AST	Aspartate transaminase
ATS	American Thoracic Society
AZO	Azathioprine
BMI	Body mass index
BP	Blood pressure
BSE	British Society of Echocardiography
cAMP	Cyclic adenosine monophosphate
CABG	Coronary artery bypasses graft
CAD	Coronary artery disease
CCB	Calcium channel blocker
CEC	Clinical Endpoints Committee
CHD	Coronary heart disease
CI	Confidence interval
CMV	Cytomegalovirus
CrCl	Creatinine clearance

CRF	Case report form
CO	Carbon monoxide
CRP	C reactive protein
CTD	Connective tissue disease
CV	Cardiovascular
CVD	Cardiovascular disease
CYC	Cyclophosphamide
dcSSc	Diffuse cutaneous systemic sclerosis
dSSc	Diffuse systemic sclerosis
DAC	Data Analysis Committee
DLCO	Single breath diffusion capacity
DP	Dorsalis pedis
DSMB	Data Safety and Monitoring Board
eGFR	Estimated glomerular filtration rate
ECG	Electrocardiograph
EMT	Epithelial to mesenchymal trans-differentiation
ENA	Extractable nuclear antigen
ERS	European Respiratory Society
ESR	Erythrocyte sedimentation rate
EULAR	European League Against Rheumatism
EUSTAR	EULAR Scleroderma Trials and Research group
FVC	Forced vital capacity
GCP	Good clinical practice
GIT	Gastrointestinal tract
GFR	Glomerular filtration rate
GORD	Gastro-oesophageal reflux disease

Hb	Haemoglobin
HAQ-DI	Health Assessment Questionnaire - Disease Indicator
HDL	High-density lipoprotein
HRCT	High resolution computed tomography
ISRCTN	International Standard Registry of Controlled Trial Numbers
IB	Investigator brochure
ICH	International Council on Harmonisation
IL	Interleukin
ILD	Interstitial lung disease
IMB	Irish Medicines Board
IV	Intravenous
lcSSc	Limited cutaneous systemic sclerosis
lSSc	Limited systemic sclerosis
LFT	Liver function test
mRSS	Modified Rodnan skin score
MCTD	Mixed connective tissue disease
MHRA	Medicines and Healthcare Regulatory Agency
MI	Myocardial infarction
MMF	Mycophenolate mofetil
MS	Mycophenolate sodium
MTX	Methotrexate
MRC	Medical Research Council
NYHA	New York Heart Association
OR	Odds ratio
PAD	Peripheral arterial disease
PAH	Pulmonary artery hypertension

PAP	Pulmonary artery pressure
PASP	Pulmonary artery systolic pressure
PCI	Percutaneous intervention
PCWP	Pulmonary capillary wedge pressure
PFT	Pulmonary function test
PGI ₂	Prostacyclin
PI	Principal Investigator
PIL	Patient information leaflet
PT	Posterior tibial
PPI	Proton pump inhibitor
PV	Plasma viscosity
R&D	Research and Development
RAP	Right atrial pressure
RA	Rheumatoid arthritis
RCT	Randomised controlled trial
REC	Research Ethics Committee
RNA	Ribonucleic acid
ROS	Reactive oxygen species
RP	Raynaud's Phenomenon
RV	Residual volume
RVSP	Right ventricular systolic pressure
SAE	Serious adverse event
SAR	Serious adverse reaction
SMR	Standardised mortality ratio
SRC	Scleroderma renal crisis
SSc	Systemic sclerosis

SUSAR	Suspected unexpected serious adverse reaction
TFR	Tendon friction rubs
TIA	Transient ischaemic attack
TLC	Total lung capacity
TMG	Trial management group
TNF	Tumour necrosing factor
TOE	Trans-oesophageal echocardiography
TSC	Trial Steering Committee
UAR	Unexpected adverse reaction
UK	United Kingdom
WBC	White blood cell
WHO	World Health Organisation

ACKNOWLEDGEMENTS

First of all, it is important for me to acknowledge the patients who took part in this study and the Raynaud's and Scleroderma Association for their funding and support. I am also grateful to the Department of Medicine, University of Dundee, for enabling me to study part-time for this doctoral thesis - support from my colleagues in the Vascular Diseases Research Unit and, latterly, Tayside Clinical Trials Unit, has been unequivocal.

In particular, I would like to express my gratitude to Professor Jill Belch, my clinical supervisor, for the opportunities afforded to me; she has been unwavering in her support and willingness to guide me. Likewise, I have benefited from the wisdom and good humour of Dr Faisal Khan, my academic supervisor, throughout this period of study.

Above all, I wish to express my heartfelt thanks to some very special people who have helped me along the way:

First and foremost, to my partner Dr Linda Orr, whose support and advice has been invaluable and, without whom, I would not have had the motivation to 'crack on'. She no longer has an excuse not to marry her intellectual match! And, to my family, Finn, Morven, Boyd and Katy, who have humoured me along the way and who have tolerated my mental and physical absences. Morven deserves a special mention for her help during the last push towards completion of this thesis.

Finally, I pay tribute to the memory of my father, Eugene, and mother, Illa, who both died during this period of study. I am sure that they would have been proud of their son's efforts and I am sorry that they are not here to see this thesis finally submitted.

'Dada Gan Iarracht'

SIGNED DECLARATION

I hereby declare that I, Stephen John McSwiggan, am the sole author of this thesis. All the references cited in this thesis have been consulted by me personally. The work, of which this thesis is a record, has been conducted entirely by me and has not been previously accepted for a higher degree.

Stephen John McSwiggan

7th July 2014

SUPERVISORY STATEMENT

I hereby declare that Stephen John McSwiggan has completed this work in the Vascular and Inflammatory Diseases Research Unit, Division of Medical Sciences, and has fulfilled the conditions of the relevant ordinance and regulations of the University of Dundee, so that he is qualified to submit the following thesis in application for the degree of Doctor of Philosophy (PhD).

Professor Jill JF Belch

Dr Faisal Khan

Vascular and Inflammatory Diseases Research Unit

Centre for Cardiovascular and Lung Biology

Division of Medical Sciences

Ninewells Hospital and Medical School

Dundee

United Kingdom

July 2014

SUMMARY

Background

Systemic sclerosis (SSc) is an autoimmune disease associated with significant mortality and morbidity. Cardiovascular causes are the single largest contributor to premature death. To date, much of the focus on managing the care of SSc patients has concentrated on traditional risk factors related to fibrotic and microvascular dysfunction. There is, however, evidence of a strong cardiovascular component to the disease and points to macrovascular dysfunction as being a key contributor to the premature mortality associated with SSc. This thesis reports on the conduct of a multi-centre, randomised, placebo-controlled clinical trial (the SSTEP Study). The aim of the study was to assess whether oral Iloprost was more effective than placebo in reducing cardiovascular events and disease progression in SSc.

Methods

Two hundred and sixteen patients with systemic sclerosis were recruited, between February 2002 and February 2005, at nine centres in the UK and Ireland. After one month placebo run-in, participants were randomised to either oral Iloprost (50-200mcg daily) or matched placebo. Baseline demographics, disease characteristics and organ screening data were collected, and participants were reviewed annually for endpoint measurements; CV events, SSc disease progression and mortality, with regular safety reviews between these annual visits. Participants were followed up for a period of 4 to 7 years.

Results

Data analysis of the combination of the two measures (survival free from death or a cardiovascular event) demonstrated a trend towards favouring Iloprost over placebo but the difference was not statistically significant (Logrank test: Chi square=0.75, p=0.39). When time to a confirmed cardiovascular endpoint alone was examined there was a suggestion of a benefit from Iloprost, but the difference was again not statistically significant (Logrank test, Chi square =0.82, p=0.37). There was no statistically significant change in the rate at which organ screening endpoints occurred throughout follow-up, and for each endpoint there was no statistically significant difference between results in patients randomised to Iloprost compared to those randomised to placebo. Withdrawal from the treatment to which the patient was randomised was frequent with 97 (45%) of the total participants discontinuing study medication. ‘On treatment’ analysis, undertaken using the endpoint of death or confirmed cardiovascular endpoint, just failed to show statistical significance at the 5% level (p=0.054).

Conclusion

The results of the SSTEP study showed that there was a trend towards favouring oral Iloprost over placebo in systemic sclerosis, though there was no statistically significant evidence to recommend its use to prevent disease progression. The high rate of withdrawal from both Iloprost and placebo hindered the possibility of demonstrating that Iloprost was effective in this study. It cannot be concluded that it is a useful therapy that may prevent premature mortality or progression to cardiovascular disease in this patient group.

ABSTRACTS AND PRESENTATIONS

The following abstract and presentations have resulted from this work:

Abstracts

Oral presentations

Systemic Sclerosis: Use of iloprost in prevention of cardiovascular disease: preliminary results. *University of Dundee 20th postgraduate symposium* (16th June 2010).

Clinical trial activity in Dundee: commercial and charity sponsored trials, the SSTEP study. *Raynaud's and Scleroderma Association 27th Annual Conference*. Moat House Hotel, Chester (26th Sept 2009).

What can you do to help yourself? Practical advice for managing Raynaud's and SSc. *Dundee Raynaud's and Scleroderma Support group*. Ninewells Hospital, Dundee (16th Jan 2009).

Poster presentations

Systemic Sclerosis Trial of Events and Progression: Progress so far. *University of Dundee Research Nurses Forum*, Ninewells Hospital, Dundee (20th Jan 2010).